Abstract:
The study aimed to investigate the potential of low dose chitooligosaccharide (COS) in ameliorating dextran sodium sulfate (DSS) induced chronic colitis by regulating microbial dysbiosis and pro-inflammatory responses. Chronic colitis was induced in BALB/c mice by DSS (4% w/v, 3 cycles of 5 days) administration. The mice were divided into four groups: vehicle, DSS, DSS + mesalamine and DSS+COS. COS and mesalamine were administered orally, daily once, from day 1 to day 30 at a dose of 20 mg/kg and 50 mg/kg respectively. The disease activity index (DAI), colon length, histopathological score, microbial composition, and pro-inflammatory cytokine expression were evaluated. COS (20 mg/kg, COSLow) administration reduced the disease activity index, and colon shortening, caused by DSS significantly. Furthermore, COSLow restored the altered microbiome in the gut and inhibited the elevated pro-inflammatory cytokines (IL-1 and IL-6) in the colon against DSS-induced chronic colitis in mice. Moreover, COSLow treatment improved the probiotic microflora thereby restoring the gut homeostasis. In conclusion, this is the first study where microbial dysbiosis and pro-inflammatory responses were modulated by chronic COSLow treatment against DSS-induced chronic colitis in Balb/c mice. Therefore, COS supplementation at a relatively low dose could be efficacious for chronic inflammatory bowel disease.
摘要:
本研究旨在探讨低剂量壳寡糖(COS)通过调节微生物菌群失调和促炎反应改善葡聚糖硫酸钠(DSS)诱导的慢性结肠炎的潜力。DSS诱导BALB/c小鼠慢性结肠炎(4%w/v,3个周期的5天)给药。将小鼠分为四组:赋形剂,DSS,DSS+美沙拉嗪和DSS+COS。口服COS和美沙拉嗪,每天一次,从第1天到第30天,分别以20mg/kg和50mg/kg的剂量。疾病活动指数(DAI),结肠长度,组织病理学评分,微生物组成,评估促炎细胞因子的表达。COS(20mg/kg,COSLow)给药降低了疾病活动指数,结肠缩短,由DSS引起的显著。此外,COSLow恢复了肠道中改变的微生物组,并抑制了结肠中升高的促炎细胞因子(IL-1和IL-6),以对抗DSS诱导的小鼠慢性结肠炎。此外,COSLow治疗改善了益生菌菌群,从而恢复了肠道稳态。总之,这是第一项通过慢性COSLow治疗Balb/c小鼠DSS诱导的慢性结肠炎来调节微生物菌群失调和促炎反应的研究.因此,以相对低的剂量补充COS对于慢性炎症性肠病可能是有效的。